What it is
An investigational dual glucagon and GLP-1 receptor agonist under clinical development as a once-weekly subcutaneous injection.
How it works
Co-agonism of glucagon and GLP-1 receptors with a balance designed to drive hepatic fat reduction and weight loss while supporting glycemic effects.
Where it's used
Under investigation primarily for metabolic dysfunction-associated steatohepatitis (MASH) and obesity in clinical trials.
Regulatory status
Not FDA-approved; investigational compound in clinical trials.
Tracking it
Pemvidutide is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem. with a half-life of about 6 days (144 h), a dose log also lets a tracker model the relative amount still in your system between doses. for titrated compounds like this one, a log that records the dose at each step is the difference between knowing your history and guessing it.
Source
Public reference
Last reviewed 2026-06-11